FI943564A7 - Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivi suutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuks ia - Google Patents

Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivi suutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuks ia Download PDF

Info

Publication number
FI943564A7
FI943564A7 FI943564A FI943564A FI943564A7 FI 943564 A7 FI943564 A7 FI 943564A7 FI 943564 A FI943564 A FI 943564A FI 943564 A FI943564 A FI 943564A FI 943564 A7 FI943564 A7 FI 943564A7
Authority
FI
Finland
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
granulocyte colony
stimulating activity
Prior art date
Application number
FI943564A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI943564A0 (fi
FI943564L (fi
Inventor
Patrice Yeh
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of FI943564A0 publication Critical patent/FI943564A0/fi
Publication of FI943564L publication Critical patent/FI943564L/fi
Publication of FI943564A7 publication Critical patent/FI943564A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI943564A 1992-01-31 1993-01-28 Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivi suutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuks ia FI943564A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9201065A FR2686900B1 (fr) 1992-01-31 1992-01-31 Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
PCT/FR1993/000086 WO1993015211A1 (fr) 1992-01-31 1993-01-28 Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant

Publications (3)

Publication Number Publication Date
FI943564A0 FI943564A0 (fi) 1994-07-29
FI943564L FI943564L (fi) 1994-07-29
FI943564A7 true FI943564A7 (fi) 1994-07-29

Family

ID=9426191

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943564A FI943564A7 (fi) 1992-01-31 1993-01-28 Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivi suutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuks ia

Country Status (8)

Country Link
US (1) US5665863A (enExample)
EP (1) EP0624200A1 (enExample)
JP (1) JPH07503844A (enExample)
CA (1) CA2125979A1 (enExample)
FI (1) FI943564A7 (enExample)
FR (1) FR2686900B1 (enExample)
NO (1) NO942858L (enExample)
WO (1) WO1993015211A1 (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
FR2719593B1 (fr) * 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
CN101070344A (zh) * 1998-04-30 2007-11-14 泰诺士公司 G－csf受体兴奋剂抗体及其筛选方法
TWI242563B (en) * 1998-04-30 2005-11-01 Tanox Inc Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor
US20030190740A1 (en) * 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
DE69926009D1 (de) * 1998-10-13 2005-08-04 Univ Georgia Res Found Stabilisierte bioaktive peptide und methoden zu ihrer identifikation, synthese und verwendung
DK1129720T3 (da) 2000-02-29 2004-09-27 Pfizer Prod Inc Stabiliseret granulocyt-kolonistimulerende faktor
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US8435939B2 (en) 2000-09-05 2013-05-07 Biokine Therapeutics Ltd. Polypeptide anti-HIV agent containing the same
DK1355942T3 (da) * 2000-12-07 2008-11-17 Lilly Co Eli GLP-1-fusionsproteiner
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003030821A2 (en) * 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
WO2003076567A2 (en) * 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
US7423007B2 (en) 2002-08-27 2008-09-09 Biokine Therapeutics Ltd. Cxcr4 antagonist and use thereof
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
EP1670428A4 (en) * 2003-10-10 2008-03-12 Univ Southern California HYBRID PROTEINS G-CSF-TRANSFERRIN
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
SI1729795T1 (sl) * 2004-02-09 2016-04-29 Human Genome Sciences, Inc. Albuminski fuzijski proteini
WO2005121174A2 (en) * 2004-06-04 2005-12-22 Five Prime Therapeutics, Inc. Novel g-csf polypeptides, polynucleotides, modulators thereof, and methods of use
IL164942A0 (en) * 2004-10-31 2005-12-18 Yeda Res & Dev The use of a protease or a protease inhibitor for the manufacture of medicaments
CA2586365A1 (en) 2004-11-05 2006-05-26 Northwestern University Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
CA2673484A1 (en) 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
NZ591235A (en) 2008-07-23 2012-07-27 Ambrx Inc Modified bovine g-csf polypeptides comprising non natural amino acid and their uses treating infections such as mastitis
UA103221C2 (uk) * 2009-01-16 2013-09-25 Тева Фармасьютікал Індастріз Лтд. Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини
US9155780B2 (en) 2009-02-11 2015-10-13 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
WO2010146578A2 (en) 2009-06-14 2010-12-23 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
US9642917B2 (en) 2011-07-25 2017-05-09 Generon (Shanghai) Corporation, Ltd. Use of G-CSF dimer in preparation of medicament for treatment of neurodegenerative diseases
US9439942B2 (en) 2012-04-24 2016-09-13 Biokine Therapeutics Ltd. Peptides and use thereof in the treatment of large cell lung cancer
US20140271538A1 (en) 2013-03-15 2014-09-18 Teva Pharmaceutical Industries Ltd. Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor for the Prevention of Neutropenia in Pediatric Patients
GB201316592D0 (en) * 2013-09-18 2013-10-30 Levicept Ltd Fusion protein
GB201412748D0 (en) * 2014-07-17 2014-09-03 Levicept Ltd Therapeutic use of P75NTR neurotrophin binding protein
CA2986705A1 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
PT3348635T (pt) 2015-09-08 2021-03-15 Japan Chem Res Novo mutante de albumina do soro humano
EP3419645B1 (en) 2016-02-23 2020-09-02 BioLineRx Ltd. Method of selecting a treatment regimen in acute myeloid leukemia (aml)
JP2017165713A (ja) 2016-03-14 2017-09-21 Ｊｃｒファーマ株式会社 血清アルブミン−２０ｋ成長ホルモン融合タンパク質
US10866963B2 (en) 2017-12-28 2020-12-15 Dropbox, Inc. File system authentication

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR871067B (en) * 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
FR2649991B2 (fr) * 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5298243A (en) * 1988-10-20 1994-03-29 Denki Kagaku Kogyo Kabushiki Kaisha Colony stimulating factor-gelatin conjugate
EP0401384B1 (en) * 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
FI901810A7 (fi) * 1989-04-13 1990-10-14 Vascular Laboratory Inc Puhtaan pro-urokinaasin plasminogeeniaktivaattorikompleksi, joka on sidottu ihmisen seerumialbumiiniin disulfidisillan välityksellä
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
AU632372B2 (en) * 1989-08-22 1992-12-24 Immunex Corporation Fusion proteins comprising gm-csf and il-3

Also Published As

Publication number Publication date
EP0624200A1 (fr) 1994-11-17
FR2686900A1 (fr) 1993-08-06
FI943564A0 (fi) 1994-07-29
WO1993015211A1 (fr) 1993-08-05
FI943564L (fi) 1994-07-29
NO942858D0 (enExample) 1994-08-01
FR2686900B1 (fr) 1995-07-21
NO942858L (no) 1994-08-01
JPH07503844A (ja) 1995-04-27
CA2125979A1 (fr) 1993-08-05
US5665863A (en) 1997-09-09

Similar Documents

Publication Publication Date Title
FI943564A7 (fi) Uusia polypeptidejä, joilla on jyvässolupesäkkeitä stimuloivaa aktiivi suutta, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuks ia
FI20010334L (fi) Granulosyyttipesäkkeitä stimuloivia polypeptidejä, niitä sisältävä farmaseuttinen koostumus, ja niiden lääketieteellinen käyttö
FI943563L (fi) Uusia biologisesti aktiivisia polypeptidejä, niiden valmistus ja niitä sisältävä farmaseuttinen koostumus
NZ218089A (en) 7-piperazinyl, 4-oxoquinolines and pharmaceutical compositions
IL92518A0 (en) Aminobenzoates,their preparation and pharmaceutical compositions containing them
FI862479L (fi) Oral farmaceutisk komposition.
IL79323A (en) Phenylethanolaminotetralines,their preparation and pharmaceutical compositions containing them
FI895047A7 (fi) Tienopyridiinit, niiden valmistus, välituoteet ja niitä sisältävät far maseuttiset koostumukset
FI844289A7 (fi) Uusia polypeptidejä, joilla on -amylaasi-estävä vaikutus, niiden käyttö ja farmaseuttiset valmistee
ZA89792B (en) Pharmaceutical compositions with improved stability
IT1214683B (it) Composizioni farmaceutiche nasali
FI893643A7 (fi) Farmaseuttisia koostumuksia
IL71951A0 (en) Polypeptides having interferon activity,their preparation and pharmaceutical compositions containing them
DE3682083D1 (de) Pharmazeutische zusammensetzungen.
FI943645L (fi) Uusia bakkatiini-III ja 10-deasetyylibakkatiini-III-johdannaisia, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
DE3583765D1 (de) Hydantoinderivate und diese enthaltende pharmazeutische zusammensetzungen.
NZ217123A (en) 7-alpha-cephalosporins, pharmaceutical compositions and intermediate compounds
IL92830A0 (en) Capsaicin derivatives,their preparation and pharmaceutical compositions containing them
DE3674040D1 (de) Pharmazeutische zusammensetzungen.
IT1213453B (it) Composizione farmaceutica.
IT8621393A0 (it) Composizioni farmaceutiche ad azione vasodilatatrice e dantianossica.
IL79469A0 (en) Substituted benzamides,their preparation and pharmaceutical compositions containing them
IL79039A0 (en) 4-oxoquinolinesulfonamides,their preparation and pharmaceutical compositions containing them
IL78432A (en) Dichloroaniline derivatives,their preparation and pharmaceutical compositions containing them
NZ217248A (en) Gem-dihalo-1,8-diamino-4-aza-octones and pharmaceutical compositions

Legal Events

Date Code Title Description
FD Application lapsed